Detalhe da pesquisa
1.
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Clin Gastroenterol Hepatol
; 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38492904
2.
Effect of Suboptimal Disease Control on Patient Quality of Life: Real-World Data from the Observational IBD-PODCAST Canada Trial.
Dig Dis Sci
; 69(5): 1636-1648, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493273
3.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet
; 399(10341): 2113-2128, 2022 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644166
4.
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Gastroenterology
; 158(8): 2139-2149.e14, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32092309
5.
BioAdvance Patient Support Program Survey: Positive Perception of Intravenous Infusions of Infliximab.
Manag Care
; 26(2): 41-48, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28273042
6.
An excess of prior irritable bowel syndrome diagnoses or treatments in Celiac disease: evidence of diagnostic delay.
Scand J Gastroenterol
; 48(7): 801-7, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23697749
7.
Exploring Patient Perspectives on a 12-Week Online, Stress Reduction Intervention in Inflammatory Bowel Disease.
Crohns Colitis 360
; 4(3): otac036, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36777414
8.
A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease.
Therap Adv Gastroenterol
; 15: 17562848221127238, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36187365
9.
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
J Crohns Colitis
; 15(10): 1694-1706, 2021 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33786600
10.
Vertebral fractures and role of low bone mineral density in Crohn's disease.
Clin Gastroenterol Hepatol
; 5(6): 721-8, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17482522
11.
Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease.
Inflamm Bowel Dis
; 10(3): 220-8, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15290915
12.
The frequency of vitamin D deficiency in adults with Crohn's disease.
Can J Gastroenterol
; 17(8): 473-8, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12945007
13.
Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database.
United European Gastroenterol J
; 2(6): 505-12, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25452846
14.
Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy.
J Crohns Colitis
; 7(2): e42-8, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22626506
15.
Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
J Crohns Colitis
; 6(7): 777-86, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22398088
16.
Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme.
J Crohns Colitis
; 6(1): 116-31, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22261537
17.
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
Clin Gastroenterol Hepatol
; 3(2): 122-32, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15704046